Trade Champions Oncology, Inc. - CSBR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Champions Oncology Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 5.02 |
| Open* | 5.01 |
| 1-Year Change* | -24.89% |
| Day's Range* | 4.8 - 5.04 |
| 52 wk Range | 3.75-7.32 |
| Average Volume (10 days) | 6,010.00 |
| Average Volume (3 months) | 178.87K |
| Market Cap | 72.25M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 13.48M |
| Revenue | 52.69M |
| EPS | -0.56 |
| Dividend (Yield %) | N/A |
| Beta | 0.80 |
| Next Earnings Date | Dec 11, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 4, 2023 | 5.02 | -0.06 | -1.18% | 5.08 | 5.08 | 4.99 |
| Dec 1, 2023 | 5.10 | 0.11 | 2.20% | 4.99 | 5.35 | 4.99 |
| Nov 30, 2023 | 5.00 | 0.15 | 3.09% | 4.85 | 5.36 | 4.85 |
| Nov 29, 2023 | 5.29 | 0.49 | 10.21% | 4.80 | 5.30 | 4.80 |
| Nov 28, 2023 | 5.05 | 0.07 | 1.41% | 4.98 | 5.19 | 4.80 |
| Nov 27, 2023 | 5.20 | -0.22 | -4.06% | 5.42 | 5.57 | 5.19 |
| Nov 24, 2023 | 5.33 | 0.47 | 9.67% | 4.86 | 5.39 | 4.85 |
| Nov 22, 2023 | 5.15 | 0.26 | 5.32% | 4.89 | 5.33 | 4.88 |
| Nov 21, 2023 | 5.22 | 0.32 | 6.53% | 4.90 | 5.39 | 4.89 |
| Nov 20, 2023 | 5.38 | 0.46 | 9.35% | 4.92 | 5.59 | 4.80 |
| Nov 17, 2023 | 5.26 | 0.13 | 2.53% | 5.13 | 5.29 | 5.13 |
| Nov 16, 2023 | 5.39 | -0.02 | -0.37% | 5.41 | 5.41 | 5.16 |
| Nov 15, 2023 | 5.48 | 0.09 | 1.67% | 5.39 | 5.56 | 5.35 |
| Nov 14, 2023 | 5.35 | 0.00 | 0.00% | 5.35 | 5.44 | 5.35 |
| Nov 13, 2023 | 5.34 | 0.27 | 5.33% | 5.07 | 5.34 | 5.07 |
| Nov 10, 2023 | 5.40 | 0.33 | 6.51% | 5.07 | 5.40 | 5.07 |
| Nov 9, 2023 | 5.29 | 0.21 | 4.13% | 5.08 | 5.43 | 5.08 |
| Nov 8, 2023 | 5.29 | -0.03 | -0.56% | 5.32 | 5.52 | 5.19 |
| Nov 7, 2023 | 5.50 | -0.07 | -1.26% | 5.57 | 5.64 | 5.48 |
| Nov 6, 2023 | 5.69 | 0.19 | 3.45% | 5.50 | 5.75 | 5.30 |
Champions Oncology, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, December 11, 2023 | ||
| Time (UTC) 21:00 | Country US
| Event Q2 2024 Champions Oncology Inc Earnings Release Q2 2024 Champions Oncology Inc Earnings ReleaseForecast -Previous - |
| Thursday, March 14, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q3 2024 Champions Oncology Inc Earnings Release Q3 2024 Champions Oncology Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total revenue | 53.87 | 49.109 | 41.04 | 32.123 | 27.067 |
| Revenue | 53.87 | 49.109 | 41.04 | 32.123 | 27.067 |
| Cost of Revenue, Total | 29.532 | 23.632 | 21.446 | 16.882 | 14.265 |
| Gross Profit | 24.338 | 25.477 | 19.594 | 15.241 | 12.802 |
| Total Operating Expense | 59.126 | 48.502 | 40.674 | 33.926 | 26.797 |
| Selling/General/Admin. Expenses, Total | 17.242 | 15.496 | 12.032 | 10.856 | 7.734 |
| Research & Development | 11.545 | 9.374 | 7.196 | 5.853 | 4.798 |
| Operating Income | -5.256 | 0.607 | 0.366 | -1.803 | 0.27 |
| Interest Income (Expense), Net Non-Operating | |||||
| Other, Net | -0.011 | -0.024 | 0.071 | -0.042 | -0.039 |
| Net Income Before Taxes | -5.267 | 0.583 | 0.437 | -1.845 | 0.231 |
| Net Income After Taxes | -5.335 | 0.548 | 0.362 | -1.975 | 0.128 |
| Net Income Before Extra. Items | -5.335 | 0.548 | 0.362 | -1.975 | 0.128 |
| Net Income | -5.335 | 0.548 | 0.362 | -1.975 | 0.128 |
| Income Available to Common Excl. Extra. Items | -5.335 | 0.548 | 0.362 | -1.975 | 0.128 |
| Income Available to Common Incl. Extra. Items | -5.335 | 0.548 | 0.362 | -1.975 | 0.128 |
| Diluted Net Income | -5.335 | 0.548 | 0.362 | -1.975 | 0.128 |
| Diluted Weighted Average Shares | 13.5416 | 14.1598 | 14.5736 | 11.8435 | 14.0961 |
| Diluted EPS Excluding Extraordinary Items | -0.39397 | 0.0387 | 0.02484 | -0.16676 | 0.00908 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -0.35524 | 0.03366 | 0.02052 | -0.14837 | 0.00908 |
| Total Extraordinary Items | |||||
| Unusual Expense (Income) | 0.807 | 0 | 0.335 |
| Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | |
|---|---|---|---|---|---|
| Total revenue | 12.561 | 13.071 | 12.773 | 14.281 | 13.745 |
| Revenue | 12.561 | 13.071 | 12.773 | 14.281 | 13.745 |
| Cost of Revenue, Total | 7.684 | 7.338 | 7.699 | 7.443 | 7.052 |
| Gross Profit | 4.877 | 5.733 | 5.074 | 6.838 | 6.693 |
| Total Operating Expense | 15.113 | 15.592 | 15.231 | 14.274 | 14.029 |
| Selling/General/Admin. Expenses, Total | 4.636 | 4.595 | 4.33 | 4.227 | 4.09 |
| Research & Development | 2.793 | 2.852 | 3.202 | 2.604 | 2.887 |
| Operating Income | -2.552 | -2.521 | -2.458 | 0.007 | -0.284 |
| Other, Net | 0.014 | -0.02 | 0.036 | -0.009 | -0.018 |
| Net Income Before Taxes | -2.538 | -2.541 | -2.422 | -0.002 | -0.302 |
| Net Income After Taxes | -2.566 | -2.561 | -2.439 | -0.016 | -0.319 |
| Net Income Before Extra. Items | -2.566 | -2.561 | -2.439 | -0.016 | -0.319 |
| Net Income | -2.566 | -2.561 | -2.439 | -0.016 | -0.319 |
| Income Available to Common Excl. Extra. Items | -2.566 | -2.561 | -2.439 | -0.016 | -0.319 |
| Income Available to Common Incl. Extra. Items | -2.566 | -2.561 | -2.439 | -0.016 | -0.319 |
| Diluted Net Income | -2.566 | -2.561 | -2.439 | -0.016 | -0.319 |
| Diluted Weighted Average Shares | 13.5068 | 13.5673 | 13.5586 | 13.5286 | 13.5224 |
| Diluted EPS Excluding Extraordinary Items | -0.18998 | -0.18876 | -0.17989 | -0.00118 | -0.02359 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.18998 | -0.1501 | -0.17989 | -0.00118 | -0.02359 |
| Unusual Expense (Income) | 0.807 |
- Annual
- Quarterly
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total Current Assets | 19.457 | 19.664 | 12.63 | 13.497 | 7.922 |
| Cash and Short Term Investments | 10.118 | 9.007 | 4.687 | 8.342 | 3.237 |
| Cash & Equivalents | 10.118 | 9.007 | 4.687 | 8.342 | 3.237 |
| Total Receivables, Net | 8.011 | 9.513 | 6.986 | 4.77 | 4.377 |
| Accounts Receivable - Trade, Net | 8.011 | 9.513 | 6.986 | 4.77 | 4.377 |
| Prepaid Expenses | 1.328 | 1.144 | 0.957 | 0.385 | 0.308 |
| Total Assets | 34.311 | 35.378 | 27.591 | 20.751 | 11.265 |
| Property/Plant/Equipment, Total - Net | 14.504 | 15.364 | 14.611 | 6.791 | 2.546 |
| Goodwill, Net | 0.335 | 0.335 | 0.335 | 0.335 | 0.669 |
| Other Long Term Assets, Total | 0.015 | 0.015 | 0.015 | 0.128 | 0.128 |
| Total Current Liabilities | 21.733 | 17.479 | 11.199 | 12.085 | 8.025 |
| Accounts Payable | 5.334 | 2.868 | 1.894 | 3.14 | 2.807 |
| Accrued Expenses | 3.478 | 3.468 | 3.049 | 3.005 | 1.18 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 12.921 | 11.143 | 6.256 | 5.815 | 4.022 |
| Total Liabilities | 29.675 | 26.282 | 20.163 | 15.433 | 9.027 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 7.942 | 8.803 | 8.964 | 3.348 | 1.002 |
| Total Equity | 4.636 | 9.096 | 7.428 | 5.318 | 2.238 |
| Common Stock | 0.014 | 0.014 | 0.013 | 0.013 | 0.012 |
| Additional Paid-In Capital | 82.013 | 81.064 | 79.945 | 77.978 | 72.924 |
| Retained Earnings (Accumulated Deficit) | -77.317 | -71.982 | -72.53 | -72.673 | -70.698 |
| Treasury Stock - Common | -0.074 | 0 | |||
| Total Liabilities & Shareholders’ Equity | 34.311 | 35.378 | 27.591 | 20.751 | 11.265 |
| Total Common Shares Outstanding | 13.5442 | 13.5224 | 13.4141 | 12.7267 | 11.6195 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.125 | 0.016 | ||
| Capital Lease Obligations | 0 | ||||
| Property/Plant/Equipment, Total - Gross | 23.134 | 20.941 | 18.567 | 9.563 | |
| Accumulated Depreciation, Total | -8.63 | -5.577 | -3.956 | -2.772 |
| Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 14.922 | 19.457 | 20.359 | 20.608 | 18.371 |
| Cash and Short Term Investments | 4.869 | 10.118 | 11.645 | 10.826 | 8.058 |
| Cash & Equivalents | 4.869 | 10.118 | 11.645 | 10.826 | 8.058 |
| Total Receivables, Net | 8.948 | 8.011 | 8.053 | 8.948 | 9.355 |
| Accounts Receivable - Trade, Net | 8.948 | 8.011 | 8.053 | 8.948 | 9.355 |
| Prepaid Expenses | 1.105 | 1.328 | 0.661 | 0.834 | 0.958 |
| Total Assets | 29.906 | 34.311 | 36.151 | 36.364 | 34.39 |
| Property/Plant/Equipment, Total - Net | 14.465 | 14.504 | 15.442 | 15.406 | 15.669 |
| Property/Plant/Equipment, Total - Gross | 23.54 | 23.134 | 22.682 | 22.071 | 21.774 |
| Accumulated Depreciation, Total | -9.075 | -8.63 | -7.24 | -6.665 | -6.105 |
| Goodwill, Net | 0.335 | 0.335 | 0.335 | 0.335 | 0.335 |
| Other Long Term Assets, Total | 0.184 | 0.015 | 0.015 | 0.015 | 0.015 |
| Total Current Liabilities | 20.382 | 21.733 | 20.797 | 18.736 | 16.62 |
| Accounts Payable | 5.759 | 5.334 | 4.298 | 4.605 | 2.537 |
| Accrued Expenses | 3.335 | 3.478 | 3.197 | 2.803 | 3.056 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 11.288 | 12.921 | 13.302 | 11.328 | 11.027 |
| Total Liabilities | 28.003 | 29.675 | 29.087 | 27.192 | 25.407 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 7.621 | 7.942 | 8.29 | 8.456 | 8.787 |
| Total Equity | 1.903 | 4.636 | 7.064 | 9.172 | 8.983 |
| Common Stock | 0.014 | 0.014 | 0.014 | 0.014 | 0.014 |
| Additional Paid-In Capital | 82.448 | 82.013 | 81.806 | 81.475 | 81.27 |
| Retained Earnings (Accumulated Deficit) | -79.883 | -77.317 | -74.756 | -72.317 | -72.301 |
| Total Liabilities & Shareholders’ Equity | 29.906 | 34.311 | 36.151 | 36.364 | 34.39 |
| Total Common Shares Outstanding | 13.4841 | 13.5442 | 13.5587 | 13.5587 | 13.5224 |
| Treasury Stock - Common | -0.676 | -0.074 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 0.548 | 0.362 | -1.975 | 0.128 | -1.476 |
| Cash From Operating Activities | 6.497 | -1.681 | 2.905 | 1.862 | -1.226 |
| Cash From Operating Activities | 1.627 | 1.184 | 0.825 | 0.606 | 0.36 |
| Non-Cash Items | 1.986 | 0.97 | 1.563 | 1.11 | 1.451 |
| Changes in Working Capital | 2.336 | -4.197 | 2.492 | 0.018 | -1.561 |
| Cash From Investing Activities | -2.384 | -3.169 | -2.22 | -0.834 | -1.226 |
| Capital Expenditures | -2.384 | -3.281 | -2.22 | -0.834 | -1.229 |
| Other Investing Cash Flow Items, Total | 0 | 0.112 | 0 | 0.003 | |
| Cash From Financing Activities | 0.207 | 1.195 | 4.42 | 1.203 | 0.013 |
| Financing Cash Flow Items | 0 | ||||
| Issuance (Retirement) of Stock, Net | 0.207 | 1.369 | 4.455 | 1.465 | 0.038 |
| Issuance (Retirement) of Debt, Net | 0 | -0.174 | -0.035 | -0.262 | -0.025 |
| Net Change in Cash | 4.32 | -3.655 | 5.105 | 2.231 | -2.439 |
| Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -2.774 | -0.335 | -0.319 | 0.548 | 0.892 |
| Cash From Operating Activities | 4.664 | 3.091 | -0.195 | 6.497 | 5.701 |
| Cash From Operating Activities | 1.663 | 1.088 | 0.528 | 1.627 | 1.059 |
| Non-Cash Items | 1.556 | 0.997 | 0.475 | 1.986 | 1.372 |
| Changes in Working Capital | 4.219 | 1.341 | -0.879 | 2.336 | 2.378 |
| Cash From Investing Activities | -2.112 | -1.358 | -0.754 | -2.384 | -1.878 |
| Capital Expenditures | -2.112 | -1.358 | -0.754 | -2.384 | -1.878 |
| Other Investing Cash Flow Items, Total | 0 | 0 | |||
| Cash From Financing Activities | 0.086 | 0.086 | 0 | 0.207 | 0.191 |
| Issuance (Retirement) of Stock, Net | 0.086 | 0.086 | 0 | 0.207 | 0.191 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | |||
| Net Change in Cash | 2.638 | 1.819 | -0.949 | 4.32 | 4.014 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Battery Management Corp | Investment Advisor | 17.9617 | 2421096 | -577 | 2023-08-25 | LOW |
| New Enterprise Associates (NEA) | Venture Capital | 12.7138 | 1713720 | 0 | 2023-08-25 | LOW |
| Morris (Ronnie) | Individual Investor | 6.3719 | 858878 | 0 | 2023-08-25 | LOW |
| Sidransky (David) | Individual Investor | 5.6906 | 767043 | 0 | 2023-08-25 | LOW |
| Ackerman (Joel) | Individual Investor | 5.5081 | 742445 | 0 | 2023-08-25 | LOW |
| Pessin (Norman H) | Individual Investor | 5.506 | 742161 | 0 | 2023-08-25 | LOW |
| Tocqueville Asset Management LP | Investment Advisor/Hedge Fund | 4.9367 | 665428 | 0 | 2023-06-30 | LOW |
| Mendelson (Daniel Newman) | Individual Investor | 1.2876 | 173561 | 17130 | 2023-10-11 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.9265 | 124891 | -1600 | 2023-06-30 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.8543 | 115153 | 1316 | 2023-06-30 | LOW |
| Essex Investment Management Company, LLC | Investment Advisor/Hedge Fund | 0.826 | 111340 | 3685 | 2023-06-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.6504 | 87671 | -28620 | 2023-06-30 | LOW |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.6293 | 84831 | 4055 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.5045 | 68007 | 0 | 2023-06-30 | LOW |
| ACT Capital Management, L.L.C. | Hedge Fund | 0.4637 | 62500 | 0 | 2022-09-30 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4371 | 58916 | 8464 | 2023-06-30 | LOW |
| Overbrook Management Corporation | Investment Advisor | 0.3597 | 48488 | 0 | 2023-06-30 | |
| LoCorr Fund Management, LLC | Investment Advisor/Hedge Fund | 0.351 | 47314 | -17614 | 2022-12-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.3326 | 44830 | -15423 | 2023-06-30 | HIGH |
| Hightower Advisors, LLC | Investment Advisor | 0.2317 | 31238 | 0 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Champions Oncology, Inc. Company profile
About Champions Oncology Inc
Champions Oncology, Inc. is engaged in creating transformative technology solutions to be utilized in oncology drug discovery and development. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Champions Oncology Inc revenues increased 19% to $36.2M. Net income decreased 14% to $892K. Revenues reflect Pharmacology services segment increase of 66% to $34.5M, Other segment increase from $101K to $1.7M. Net income was offset by research and development increase of 32% to $6.8M (expense), general and administratiojn increase of 32% to $5.9M (expense).
Equity composition
Common Stock $.001 Par, 01/11, 50M auth., 36,853,000 issd. less 1,236,000 shs. in Treas. @ $292K. Insiders & strategic holders own 64.79%. Public Offering 9/85, 40M Units (1 sh. com. + 3 warrants) @ $.01 by the Company. 02/07, Name changedfrom Champions Sports Inc.08/15, 1-for-12 Reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 619
855 N. Wolfe Street
BALTIMORE
MARYLAND 21205
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com